Patched genes and uses related thereto

• US 6,429,354 B1
• Filed: 08/22/1997
• Issued: 08/06/2002
• Est. Priority Date: 10/07/1994
• Status: Expired due to Term

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.), Regents of the University of California (University of California)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.), Regents of the University of California (University of California)
• Inventors: Johnson, Ronald L., Goodrich, Lisa V., Epstein, Ervin Jr., Scott, Matthew P.
• Primary Examiner(s): Ketter, James
• Assistant Examiner(s): SCHNIZER, RICHARD A
• Application Number:
  US08/918,658
• Time in Patent Office: 1,810 Days
• Field of Search: 435/325, 435/350, 435/351, 435/352, 435/366, 800/8, 800/10, 800/14
• US Class Current: 800/18
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2227/40 Fish
• CPC Class Codes: C07K 14/43563 from insects
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

Methods for isolating patched genes, particularly mammalian patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The cancers may be familial, having as a component of risk an inherited genetic predisposition, or may be sporadic. The patched and hedgehog genes are useful: in creating transgenic animal models for these human cancers. The patched nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated 15 physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene.

Claims

1. A transgenic mouse whose genome comprises disruption of at least one allele of a patched locus, wherein said disruption predisposes said mouse to develop a proliferative disorder.

2. The mouse of claim 1, which is predisposed to develop a carcinoma.

3. The mouse of claim 2, which is predisposed to develop a basal cell carcinoma.

4. The mouse of claim 1, which is predisposed to develop a medulloblastoma.

5. The transgenic mouse of claim 1, wherein said disruption results in a mutation of the patched allele selected selected from, a deletion of one or more nucleotides of the patched allele, and an insertion of one or more nucleotides in the patched allele.

6. The transgenic mouse of claim 1, wherein said disruption results in a mutation of the coding sequence of the patched allele.

7. The transgenic mouse of claim 1, wherein said disruption is caused by insertion if a transgene comprising (i) a patched gene sequence that directs homologous recombination of the transgene with the patched allele, and (ii) a marker sequence which provides a detectable signal for identifying the presence of the transgene in the genome of the animal.

10. Tissue from a transgenic mouse of claim 1.

12. A cell from a transgenic mouse of claim 1.

13. mouse of claim 1, which is predisposed to develop polydactyly.

14. The mouse of claim 1, which is predisposed to develop syndactyly.

8. A genetically engineered mouse embryo, wherein both patched alleles are disrupted.

9. Tissue from a transgenic mouse embryo of claim 8.

11. A cell from a transgenic mouse embryo of claim 8.